Artificial intelligence-assisted meta-analysis of the frequency of ACE I/D polymorphisms in centenarians and other long-lived individuals

Lingxuan Li and Shin Murakami*

Department of Basic Sciences, College of Osteopathic Medicine, Touro University California, Vallejo, CA 94592.

*, Corresponding author, Shin Murakami, PHD, FGSA

Abstract

1

2 3 4

5 6

7

8 9

10 11 12

13

14 15

16 17

18

19 20

21

22 23

24

25 26

27

28

29

30

31

32 33

34

35 36

37

38

39

40 41

42 43

44

Current research on the angiotensin-converting-enzyme (ACE) gene has yielded controversial results on whether different ACE polymorphisms are linked with human longevity. ACE polymorphisms are a risk factor for Alzheimer's disease and age-onset diseases that may contribute to the mortality of older people. Our goal is to consolidate existing studies with assistance from artificial intelligence and machine-learning-assisted software to come to a more precise understanding of the role of the ACE gene in human longevity. The I (insertion) and D (deletion) polymorphisms in the intron are correlated with the levels of circulating ACE; homozygous D (DD) is high and homozygous I (II) is low. Here, we performed a detailed metaanalysis of the I and D polymorphisms using centenarians (100+ years old), long-lived subjects (85+ years old), and control groups. ACE genotype distribution was analyzed across a total of 2,054 centenarians and 12,074 controls, as well as 1,367 long-lived subjects between the ages of 85-99, using the inverse variance and random effects methods. The ACE DD genotype was found to be favored in centenarians (OR: 1.41 [95% CI: 1.19-1.67], P < 0.0001) with a heterogeneity of 32%, and the II genotype slightly favored the control groups (OR: 0.81 [95% CI: 0.66-0.98], P = 0.03) with a heterogeneity of 28%, corroborating results from previous metaanalyses. Novel to our meta-analysis, the ID genotype was found to be favored in control groups (OR: 0.86 [95% CI: 0.76-0.97], P = 0.01) with a heterogeneity of 0%. The long-lived group showed a similar positive association between the DD genotype and longevity (OR: 1.34 [95% CI: 1.21-1.48, P < 0.0001) and a negative association between the II genotype and longevity (OR: 0.79 [95% CI: 0.70-0.88], P < 0.0001). The long-lived ID genotype did not show significant findings (OR: 0.93 [95% CI: 0.84-1.02], P = 0.79). In conclusion, the results suggest a significant positive association of the DD genotype with human longevity. However, despite the previous study, the results do not confirm a positive association of the ID genotype with human longevity. We suggest a few paradoxical observations: (1) inhibition of ACE can increase longevity in model systems from nematodes to mammals, seemingly opposite to the finding in humans; (2) exceptional longevity associated with homozygous DD is also associated agerelated diseases with higher mortality risks in homozygous DD. We discuss ACE, longevity, and age-related diseases.

Introduction

Human life expectancy has increased in the past millennia since the studies of longevity in ancient Greek and Roman populations (Montagu, 1994; Batrinos, 2008; Roser et al., 2013). The study of aging, including the biology of aging and populations of older people, has suggested that longevity is influenced by a combination of genetic, lifestyle, and environmental factors (reviewed in Weinert et al., 2003). The search for genetic causes of longevity has implicated several possible candidate genes, including SIRT1, APOE, FOXO3A, ACE, ATM, NOS1, NOS2, KLOTHO and IL6 (reviewed in Revelas et al., 2018; Costa et al., 2019). Of them, ACE encodes an angiotensin-converting enzyme, which has two functions with opposing effects on health (Duc et al., 2020; Duc et al., 2021). Firstly, ACE is an essential enzyme for hemodynamic control via the renin-angiotensin-aldosterone system and the kinin-kallikrein system. ACE converts the inactive angiotensin I to the active angiotensin II, a potent vasoconstrictor, and inactivates bradykinin, a potent vasodilator. ACE inhibitors are one of the first-line treatments for hypertension and congestive heart failure. In this function, ACE inhibition is beneficial to health through controlling hypertension. Secondly, ACE is an amyloid-degrading enzyme that can reduce the proteo-toxicity of amyloid. Importantly, ACE, when altered, is a risk factor gene in Alzheimer's disease (Vahdati Nia et al., 2017; Murakami and Lacayo, 2022). ACE alterations are associated with Alzheimer's disease (discussed in Duc et al., 2021). In this function, ACE inhibition may be deleterious to the health through amyloid toxicity. Thus, the effect of ACE on longevity may differ depending on the health conditions of advanced aging (Duc et al., 2021). Thus, we reason that long-lived groups should be included in this study.

The ACE gene is located on chromosome 17q23. The ACE I/D polymorphisms were first identified in 1990, which are characterized by the presence (insertion, I) or absence (deletion, D) of a 287-bp (base pair) Alu repeat sequence in intron 16 (Rigat et al., 1990). The I/D polymorphisms correlated with the serum levels of circulating ACE; the D-allele is higher and the I-allele is lower (Tiret et al., 1992). The DD individuals have approximately twice the plasma ACE levels as the II individuals do (Rigat et al., 1990; Tomita et al., 1996). Other meta-analyses have also shown a positive association between the D-allele and increased risk of essential hypertension (Li et al., 2011), ischemic stroke (Zhang et al., 2012), coronary artery disease (Zintzaras et al., 2008), left ventricular hypertrophy (Li et al., 2012) and pneumonia (Nie et al., 2014). In addition, the D-allele has been linked with higher mortality rates from COVID-19 (Yamamoto et al., 2020).

Paradoxically, the ACE D allele is associated with the risk of cardiovascular disease, hypertension, Alzheimer's disease, and other common causes of death in older people, while a previous study noted an increased frequency of the DD genotype among a group of centenarians from France (Schachter et al., 1994). Since then, centenarian studies have been performed across different cohorts, resulting in conflicting results. A more recent study suggests that the DD genotype and the D allele are enriched in centenarians (Garatachea et al., 2013), while another study suggests that no significant difference among the I and D alleles (Choi et a., 2003; Oscanoa, et al., 2020). In this meta-analysis, we further consolidated these findings to more precisely determine whether or not the D polymorphism is enriched in centenarians and long-lived individuals.

Methods

Nomenclature, PRISMA and Database search

Due to nomenclature inconsistency among studies, we used I (Insertion) and D (deletion) alleles as follows: The genotypes were referred to as homozygous insertion (II), heterozygous insertion/deletion (ID), and homozygous deletion (DD). The I and D polymorphisms were referred to as I/D. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher et al., 2009) and performed a meta-analysis as described (Antos et al., 2021) with updates described in PRISMA 2020 (Page et al., 2021). We performed a literature search to collect all publications on ACE I/D polymorphisms in centenarians published before May 25, 2022. A total of 80 studies were obtained from the Human Genomic Aging Resource's Longevity Map database, Scopus, PubMed, and Google Scholar using the keywords "ACE" OR "angiotensin-converting enzyme" AND "longevity" OR "centenarian" OR "nonagenarian" (subjects 90+ years). Studies of all languages were included. The titles and abstracts of each article were imported to Colandr (Cheng et al., 2018) which uses Al and machine-learning algorithms to determine an article's relevance based on text-based evidence. Of the 80 studies initially identified, 37 were excluded as duplicates. The remaining 43 articles were then screened in Colandr according to specified inclusion criteria.

Inclusion criteria

Studies were included if they met all of the following conditions: (1) evaluation of the ACE I/D polymorphisms and longevity; (2) case-control study design; (3) study provides sample size, genotype data, odds ratio (OR) and 95% confidence interval (CI), or the data necessary to calculate the results. The exclusion criteria of the studies were as follows: (1) not relevant to ACE I/D polymorphisms or longevity; (2) review or meta-analysis; (3) minimum long-lived population age < 85 years or unspecified; (4) no control group or maximum control group age > 85 years. Data was then separated into centenarian-only and long-lived (85+ years old) sections. Studies were included in the centenarian-only section if the mean population age was > 100. In total, we obtained 13 papers that met all our inclusion criteria for centenarians and 19 papers for the long-lived group.

Data extraction

Data were extracted independently by the author and an assistant, and any discrepancies were settled by consensus. The data extracted included the author's name, year of publication, ethnicity of the study population, sample size, and genotype numbers in long-lived and control groups. Allele frequencies were calculated if not directly reported. If the study had multiple control groups of varying age ranges, the control group was defined as all individuals \leq 85 years of age, and data was extracted accordingly.

Data synthesis and assessment of the risk of bias

To determine the association between ACE genotype and longevity, the odds ratio (OR) with the corresponding 95% confidence interval (CI) was calculated for each genotype (DD, ID, and II). All statistical analyses were performed using The Cochrane Collaboration's Review Manager (RevMan) Version 5.4 using the random effects statistical model and inverse variance methods. The risk of bias in the studies was performed as described by Antos et al., 2021. The result was visualized with Risk-of-bias VISualization (robvis) ROBINS-1 (Sterne et al., 2016; McGuinness et al., 2021). Bias due to deviations from intended interventions did not apply to this metanalysis, as participants were categorized by age and could not be blinded in which group they were assigned.




Figure 1. Flow diagram of the literature search. A total of 80 studies were gathered from SCOPUS (n = 39), PubMed (n = 26) and Google Scholar (n = 15). Excluding 33 duplicates and 4

studies with irrelevant titles, 43 remaining studies were selected for abstract examination. Following the abstract screening, 2 studies were excluded for having the wrong study design and 13 studies were excluded for defining their minimum long-lived population age to be < 85 years of age. The full-text review was performed on the remaining 28 studies, and 9 of those were excluded as the data was not usable, meaning that the study collected and presented data in a form other than the frequency of individuals genotypes and that the frequency of genotypes was not able to be calculated from the data available.

Results

I. Centenarian results:

Our literature search is summarized in Figure 1. The extracted data of centenarians from the identified studies are summarized in Table 1. The meta-analysis included 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang et al., 2010), involving a total of 2,054 centenarians and 10,986 controls. Ethnicities of the studied populations were Caucasian (n = 10), Korean (n = 1), Uyghur (n = 1) and Han Chinese (n = 1). This meta-analysis investigated what age groups could be analyzed. We found three age groups that consistently showed up among the previous studies, resulting in centenarians (100+ years old), long-lived groups (85+ years old), and control groups. The range of the control groups was diverse among previous studies. We set the ages of control groups as 18-85 year old which was judged to be inclusive to most of the studies.

The major differences from the previous meta-analysis were as follows. Firstly, we used different age groups for a more precise understanding of the effect of ACE on longevity. The previous meta-analysis compared the frequencies of various combinations of I and D (i.e., DD vs. II; DD vs. II; DD vs. II; DD vs. II; and DD vs. ID + II) (Garatachea et al., 2013), which lacked comparisons among different age groups. Secondly, we excluded a study (Paolisso et al., 2001), which was used in the previous meta-analysis (Garatachea et al., 2013) for the following reason: The excluded study used 62-88 years old, which overlapped with the age range for the long-lived group (85+ years old) commonly used in previous studies (see II. Long-Lived Results). Finally, we incorporated AI-assisted software to reduce the burden of the meta-analysis studies.

Table 1. Characteristics of studies on *ACE* I/D polymorphisms in centenarians. A total of 13 studies were included that looked at the frequency of different *ACE* I/D polymorphisms in centenarians.

	Year	Се	ntenarian	(Control	Ethnicity
		# of subject s	Age (years) Mean ± SD	# of subject s	Age (years) Range	
Schachter et al.	1994	310	100.71 ± 0.13	164	20-70	Caucasian
Faure-Delanef et al.	1998	150	100.6	74	20-70	Caucasian
Bladbjerg et al.	1999	185	>100	199	20-64	Caucasian
Blanche et al.	2001	560	103.1	560	18-70	Caucasian
Panza et al.	2002	63	100.3 ± 1.9	204	19-80	Caucasian
Choi et al.	2003	102	102.4 ± 2.6	7229	20-85	Korean
Panza et al.	2003	82	100 ± 2	252	19-70	Caucasian
Wufuer et al.	2004	42	103.0 ± 3.0	53	65-70	Uyghur
Seripa et al.	2006	64	100.28 ± 1.86	1191	22-59	Caucasian
Nacmias et al.	2007	111	102.4 ± 2.6	192	84 ± 18.2	Caucasian
Zhang et al.	2010	27	>100	79	60-70	Han Chinese
Fiuza-Luces et al.	2011	65	101.7 ± 1.8	283	21.2 ± 2.0	Caucasian
Pereira da Silva et al.	2018	253	100.26 ± 1.98	268	67.51 ± 3.25	Caucasian

As shown in Figure 2, the association between the DD genotype and exceptional longevity was analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang et al., 2010). The DD genotype was more frequent among centenarians than in controls, with an OR of 1.41 (95% CI: 1.19-1.67, P < 0.0001) with mild heterogeneity (32%), indicating a significant positive association between the DD genotype and longevity.




Figure 2: Comparison of DD genotype frequency in centenarians and control groups. The ages of centenarians and control groups are as described in Table 1.

As shown in Figure 3, the association between the ID genotype and exceptional longevity was analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang et al., 2010). The ID genotype was found to have an OR of 0.86 (95% CI: 0.76-0.97, P = 0.01) with no evidence of heterogeneity (0%), indicating a significant negative association between the ID genotype and longevity.




Figure 3: Comparison of ID genotype frequency in centenarians and control groups. The ages of centenarians and control groups are described in Table 1.

As shown in Figure 4, the association between the II genotype and exceptional longevity was analyzed in 13 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Nacmias et al., 2007;

Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Zhang et al., 2010). The II genotype was found to have an OR of 0.81 (95% CI: 0.66-0.98, P = 0.03) with mild heterogeneity (28%), indicating a significant negative association between the II genotype and longevity.




Figure 4: Comparison of II genotype frequency in centenarians and control groups. The ages of centenarians and control groups are as described in Table 1.

II. Long-Lived Results:

Table 2 summarizes the data of long-lived groups. The meta-analysis included 19 studies, with 13 centenarian-only studies, and 5 studies that included both nonagenarians and centenarians (Arkhipova et al., 2014; Kolovou et al., 2014; Lo Sasso et al., 2012; Oscanoa et al., 2020; Yang et al., 2009), and 1 study with individuals 85 years and older (Heijmans et al., 1999), involving a total of 3,421 long-lived individuals (85+ years old) and 11,959 controls. Ethnicities of the studied populations were Caucasian (n = 13), Korean (n = 1), Uyghur (n = 1), Han Chinese (n = 1), Russian/Yakut (n = 1), and Peruvian (n = 1).

The association between the DD genotype and exceptional longevity was analyzed in 18 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Kolovou et al., 2014; Lo Sasso et al., 2012; Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; Zhang et al., 2010). The DD genotype was found to have an OR of 1.32 (95% CI: 1.19-1.47, P < 0.00001) with mild heterogeneity (30%), indicating a significant positive association between the DD genotype and longevity.

Table 2. Characteristics of studies on *ACE* I/D polymorphisms in long-lived individuals (85+ years old).

	Year	Lo	ong-lived		Control	Ethnicity
		# of subject s	Age (years) Mean ± SD	# of subject s	Age (years) Range/Mean ± SD	
Schachter et al.	1994	310	100.71 ± 0.13	164	20-70	Caucasian
Faure-Delanef et al.	1998	150	100.6	74	20-70	Caucasian
Bladbjerg et al.	1999	185	>100	199	20-64	Caucasian
Heijmans et al.	1999	353	85-100	250	18-40	Caucasian
Blanche et al.	2001	560	103.1	560	18-70	Caucasian
Panza et al.	2002	63	100.3 ± 1.9	204	19-80	Caucasian
Choi et al.	2003	102	102.4 ± 2.6	7229	20-85	Korean
Panza et al.	2003	82	100 ± 2	252	19-70	Caucasian
Wufuer et al.	2004	42	103.0 ± 3.0	53	65-70	Uyghur
Seripa et al.	2006	64	100.28 ± 1.86	1191	22-59	Caucasian
Nacmias et al.	2007	111	102.4 ± 2.6	192	84 ± 18.2	Caucasian
Yang et al.	2009	399	>90	302	<60	Han Chinese
Zhang et al.	2010	27	>100	79	60-70	Han Chinese
Fiuza-Luces et al.	2011	65	101.7 ± 1.8	283	21.2 ± 2.0	Caucasian
Lo Sasso et al.	2012	361	97	394	39	Caucasian
Arkhipova et al.	2014	44	>90	115	60-74	Russian, Yakut
Kolovou et al.	2014	198	≥90	105	18-79	Caucasian
Pereira da Silva et al.	2018	253	100.26 ± 1.98	268	67.51 ± 3.25	Caucasian
Oscanoa et al.	2020	6	>85	14	<65	Peruvian

	Long-Lived w/DD Control w/DD		Odds Ratio			Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Schachter 1994	134	310	42	164	6.2%	2.21 [1.46, 3.35]	1994	
Faure-Delanef 1998	47	150	20	74	2.8%	1.23 [0.66, 2.29]	1998	+-
Bladbjerg 1999	49	185	51	199	5.2%	1.05 [0.66, 1.65]	1999	+
Heijmans 1999	103	353	66	250	8.2%	1.15 [0.80, 1.65]	1999	 -
Blanche 2001	196	560	171	560	17.2%	1.22 [0.95, 1.57]	2001	 -
Panza 2002	30	63	69	204	3.3%	1.78 [1.00, 3.16]	2002	-
Choi 2003	15	102	1041	7229	3.5%	1.02 [0.59, 1.78]	2003	
Panza 2003	38	82	100	252	4.3%	1.31 [0.79, 2.17]	2003	+
Wufuer 2004	40	144	13	123	2.3%	3.25 [1.65, 6.43]	2004	
Seripa 2006	30	64	510	1191	4.2%	1.18 [0.71, 1.95]	2006	 -
Nacmias 2007	57	111	82	192	4.9%	1.42 [0.89, 2.26]	2007	+-
Yang 2009	52	399	43	302	5.7%	0.90 [0.58, 1.39]	2009	+
Zhang 2010	8	27	7	79	0.8%	4.33 [1.39, 13.45]	2010	
Fiuza-Luces 2011	49	111	175	434	6.1%	1.17 [0.77, 1.78]	2011	+
Lo Sasso 2012	161	361	132	394	12.4%	1.60 [1.19, 2.15]	2012	-
Kolovou 2014	78	198	36	100	4.3%	1.16 [0.70, 1.90]	2014	+
Pereira da Silva 2019	104	253	91	268	8.5%	1.36 [0.95, 1.94]	2019	 •
Oscanoa 2020	0	6	2	14	0.1%	0.38 [0.02, 9.26]	2020	-
Total (95% CI)		3479		12029	100.0%	1.34 [1.21, 1.48]		♦
Total events	1191		2651					
Heterogeneity: Chi² = 21	6.63, df = 17 (F	9 = 0.06); I ^z = 36%					0.01 0.1 1 10 100
Test for overall effect: Z	= 5.51 (P < 0.0	00001)						0.01 0.1 1 10 100 Favors control Favors long-lived
	•							ravora control ravora long-lived

Figure 5. Comparison of DD genotype frequency in long-lived and control groups. The ages of long-lived and control groups are described in Table 1.

As shown in Figure 6, the association between the ID genotype and exceptional longevity was analyzed in 18 studies (Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Kolovou et al., 2014; Lo Sasso et al., 2012; Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; Zhang et al., 2010).

The ID genotype was found to have an OR of 0.92 (95% CI: 0.84-1.02, P = 0.11) with no evidence of heterogeneity (0%). There was no significant difference in the frequency of the ID genotype between the long-lived (85+ years old) and control groups.

	Long-Lived	w/ID	Control w/ID		Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Schachter 1994	148	310	91	164	6.1%	0.73 [0.50, 1.07]	1994	. - •
Faure-Delanef 1998	82	150	38	74	2.9%	1.14 [0.65, 2.00]	1998	+
Bladbjerg 1999	95	185	102	199	5.5%	1.00 [0.67, 1.50]	1999	+
Heijmans 1999	177	353	122	250	8.4%	1.06 [0.76, 1.46]	1999	+
Blanche 2001	261	560	288	560	16.1%	0.82 [0.65, 1.04]	2001	
Panza 2002	27	63	109	204	2.7%	0.65 [0.37, 1.16]	2002	: -
Panza 2003	34	82	118	252	3.5%	0.80 [0.49, 1.33]	2003	
Choi 2003	52	102	3549	7229	5.8%	1.08 [0.73, 1.59]	2003	+
Wufuer 2004	59	144	56	123	3.8%	0.83 [0.51, 1.35]	2004	·
Seripa 2006	28	64	526	1191	3.5%	0.98 [0.59, 1.63]	2006	· -
Nacmias 2007	40	111	84	192	3.8%	0.72 [0.45, 1.17]	2007	•
Yang 2009	179	399	130	302	9.8%	1.08 [0.80, 1.46]	2009	+
Zhang 2010	9	27	26	79	1.0%	1.02 [0.40, 2.58]	2010	· —
Fiuza-Luces 2011	47	111	191	434	5.0%	0.93 [0.61, 1.42]	2011	
Lo Sasso 2012	156	361	172	394	10.7%	0.98 [0.74, 1.31]	2012	· †
Kolovou 2014	85	198	46	100	3.8%	0.88 [0.54, 1.43]	2014	· -
Pereira da Silva 2019	111	253	119	268	7.4%	0.98 [0.69, 1.38]	2019	+
Oscanoa 2020	4	6	3	14	0.2%	7.33 [0.88, 61.33]	2020	
Total (95% CI)		3479		12029	100.0%	0.93 [0.84, 1.02]		•
Total events	1594		5770					
Heterogeneity: Chi² = 1:	2.23, df = 17 (P = 0.79); I ² = 0%					0.01 0.1 1 10 100
Test for overall effect: Z	= 1.60 (P = 0)	11)						Favors control Favors long-lived
								ravors control ravors long-lived

Figure 6. Comparison of ID genotype frequency in long-lived and control groups. The ages of long-lived and control groups are described in Table 1.


 As shown in Figure 7, the association between the II genotype and exceptional longevity was analyzed in 19 studies (Arkhipova et al., 2014; Bladbjerg et al., 1999; Blanche et al., 2001; Choi et al., 2003; Pereira da Silva et al., 2018; Faure-Delanef et al., 1998; Fiuza-Luces et al., 2011; Kolovou et al., 2014; Lo Sasso et al., 2012; Nacmias et al., 2007; Oscanoa et al., 2020; Panza et al., 2002, 2003; Schachter et al., 1994; Seripa et al., 2006; Wufuer et al., 2004; Yang et al., 2009; Zhang et al., 2010). Arkhipova et al., 2014 only provided raw frequency data for the II genotype and thus was not included in the DD or ID analyses. The II genotype was found to have an OR of 0.80 (95% CI: 0.71-0.90, P = 0.002) with mild heterogeneity (30%), indicating a significant negative association between the II genotype and longevity. The risk of bias of the studies was assessed using ROBINS-1 (Method). As shown in Figure 8, the result suggests an overall low risk of bias.

	Long-Live	d w II	Contro	l w II	Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Schachter 1994	56	310	31	164	5.8%	0.95 [0.58, 1.54]	1994	_
Faure-Delanef 1998	21	150	16	74	2.6%	0.59 [0.29, 1.21]	1998	
Bladbjerg 1999	41	185	46	199	6.0%	0.95 [0.59, 1.53]	1999	+
Heijmans 1999	73	353	62	250	9.2%	0.79 [0.54, 1.16]	1999	
Blanche 2001	103	560	101	560	14.9%	1.02 [0.76, 1.39]	2001	+
Panza 2002	6	63	26	204	1.6%	0.72 [0.28, 1.84]	2002	
Panza 2003	10	82	34	252	2.4%	0.89 [0.42, 1.89]	2003	
Choi 2003	35	102	2639	7229	8.1%	0.91 [0.60, 1.37]	2003	-
Wufuer 2004	45	144	54	123	5.5%	0.58 [0.35, 0.96]	2004	
Seripa 2006	6	64	155	1191	1.9%	0.69 [0.29, 1.63]	2006	
Nacmias 2007	14	111	26	192	2.8%	0.92 [0.46, 1.85]	2007	-
Yang 2009	168	399	129	302	15.0%	0.98 [0.72, 1.32]	2009	+
Zhang 2010	10	27	46	79	1.7%	0.42 [0.17, 1.04]	2010	
Fiuza-Luces 2011	15	111	68	434	3.8%	0.84 [0.46, 1.54]	2011	
Lo Sasso 2012	44	361	90	394	8.9%	0.47 [0.32, 0.69]	2012	
Arkhipova 2014	14	44	47	115	2.5%	0.68 [0.32, 1.41]	2014	
Kolovou 2014	35	198	18	100	3.5%	0.98 [0.52, 1.83]	2014	
Pereira da Silva 2019	15	253	44	268	3.6%	0.32 [0.17, 0.59]	2019	
Oscanoa 2020	2	6	9	14	0.3%	0.28 [0.04, 2.09]	2020	· ·
Total (95% CI)		3523		12144	100.0%	0.79 [0.70, 0.88]		•
Total events	713		3641					
Heterogeneity: Chi ² = 27	7.28, df = 18	(P = 0.0	$(7); I^2 = 34$	1%				
Test for overall effect: Z		•						0.01 0.1 1 10 100 100
		,						Favors control Favors long-lived

Figure 7. Comparison of II genotype frequency in long-lived and control groups. The ages of long-lived and control groups are described in Table 1.

291

292



D2: Bias due to selection of participants.

D3: Bias in classification of interventions.

D4: Bias due to deviations from intended interventions.

D5: Bias due to missing data.

D6: Bias in measurement of outcomes.

D7: Bias in selection of the reported result.

Moderate

Low

No information




Figure 8B. Summary plot showing the assessment of the risk of bias using ROBINS-1.

Discussion:

Centenarians are the fastest-growing demographic group of the world's population, having roughly doubled every decade since 1950 (Wilcox et al., 2011). It has been nearly a decade since the most recent meta-analysis has been published in 2013 (Garatachea et al., 2013) and additional studies on centenarians and nonagenarians have been conducted that further elucidate the association between *ACE* genotype and longevity. In addition, the use of AI and machine-learning software has aided in the search and screening process to compile even more studies and process the associated data. Our meta-analysis suggests, with increased confidence, that there is a significant positive association of the DD genotype with exceptional longevity, across populations of different ethnicities. It has been reported that serum ACE levels correlate in the order of DD > ID > II in which DD is the highest (Rigat et al., 1990; Tiret et al., 1992; Tomita et al., 1996). The higher levels of ACE were correlated with increased lifespans, especially more in centenarians than in long-lived controls.

The results present a couple of paradoxes in which the D-allele has been reported as a risk factor for hypertension (Li et al., 2011), CVD (Zintzaras et al., 2008), pneumonia (Nie et al., 2014) and COVID-19 (Yamamoto et al., 2020), all of which are major causes of death in older people. However, the DD genotype has been associated with a decreased risk of Alzheimer's disease, potentially due to ACE's ability to inhibit amyloid beta aggregation and degrade A beta-(1-40) (Hu et al., 2001; Kölsch et al., 2005; Lehmann et al., 2005). Although the protective effect of the D-allele against Alzheimer's disease does not fully explain the higher proportion of DD individuals in centenarian cohorts, the D-allele or DD genotype may impart a health risk while also providing a long-term longevity advantage. The middle-life crisis theory of aging (Murakami et al., 2011; Murakami, 2013; Machino et al., 2014; Le et al., 2021), in which midlife events are the catalyst for the transition from normal aging to a more advanced pathological state, can be used to explain ACE's dual functions as an angiotensin-converting enzyme and an amyloid-degrading enzyme (Le et al., 2021); low levels of ACE plasma activity, associated with the II genotype, may initially confer stress resistance before midlife, but will be insufficient to counter the abnormal accumulation of beta-amyloid when it begins and thus lead to higher mortality

rates earlier in the aging process due to AD, while DD individuals who had survived midlife comorbidities would now have lower mortality rates from AD. However, this does not fully explain the ACE paradox, as Alzheimer's disease is only one of many diseases that affect older people. As the full role of ACE in the human body has not been determined, the D-allele may have some neuroendocrine or immunomodulatory functions that have yet to be discovered (Costerousse et al., 1993) that may further explain ACE's role in longevity. It raises an unanswered key question how exceptional longevity is associated with positive risks of ageonset diseases that may increase the risk of mortality.

Another paradox is that inhibition of ACE by mutations or drugs can extend lifespans in model systems from nematodes, fruit flies, and mammals (reviewed in Le et al., 2021; Egan et al., 2022). The observation raises awareness that life-extension interventions in model systems may be different from exceptional longevity in humans. Thus, it raises another unanswered key question of whether or not exceptional longevity in humans shares common underlying mechanisms with life extension in model systems.

Our meta-analysis includes a comprehensive review of studies done on centenarians, from Schachter's initial study in 1994 up to the present, for a total of 2,054 centenarians. We did not limit the literature search to only studies written in English, thus our data represents all of the current *ACE* centenarian studies in the databases searched. The results corroborated the positive association between the DD genotype and exceptional longevity and the negative association between the II genotype and exceptional longevity that had been noted in previous meta-analyses. A novel finding was that the ID genotype, which had previously shown no significant associations with longevity, was found to have a significant negative association with longevity in the centenarian-only analysis.

It is implicated that the effect of ACE on health may differ among different age groups (Duc et al., 2021). Thus, we compared the centenarian-only data with the long-lived (85+ years old) data. We found that the distribution of ACE DD and II genotypes were consistent across both age groups, with strong associations in the DD genotype with exceptional longevity and with negative associations in the II genotype. Interestingly, the ID genotype had a significant negative association among centenarians but did not show a significant association among long-lived groups. The straightforward interpretations are as follows: (1) The DD genotype is associated with centenarians and is long-lived, while the D alleles follow the inheritance pattern of autosomal recessive; (2) The II genotype is negatively associated with longevity in both age groups; (3) The ID genotype shows a weakly negative association with centenarians, while the trend was not significant in long-lived control. Thus, more detailed studies with a series of ages will be needed.

The limitations of this study are as follows. Firstly, it can be summarized as a general limitation of the meta-analysis method. Each search engine list the papers which are indexed by its criteria, which may miss relevant studies. We included three search engines to reduce this risk of missing studies. Secondly, related to the first limitation is that the criteria to analyze the data rely on the criteria used in each study. For example, control groups of the past studies ranged

broadly and diverse (18-85 years old). There was a lack of detailed age groups to compare the effect of ACE. Thus, we were not able to have a series of ages to define age-dependent enrichment of the ACE D and I alleles. Thirdly, another limitation is that the vast majority of the centenarian studies on ACE used Caucasian populations. Selectively analyzing the studies of Caucasian populations gives the same results as the pooled data, indicating that there were no major differences in association across ethnicity within this present review. However, there were not enough Asian studies to sufficiently analyze the strength of association within Asian populations only. We also did not find any studies on ACE polymorphisms in Hispanic/Latino or Black centenarian cohorts in our literature search. For future meta-analyses, a greater diversity of such studies should be taken to better illuminate the role of ACE in aging populations across all different environmental or lifestyle risk factors.

Conclusions:

Our meta-analysis suggests a significant positive association between the ACE DD genotype with centenarians and long-lived groups. Although ACE polymorphisms are a risk factor for Alzheimer's disease and age-onset diseases that may contribute to mortality, the ACE DD genotype but not the ID genotype was in favor of exceptional longevity over the mortality expected in older people. The DD genotype is associated with a reduced risk of Alzheimer's disease and increased longevity. It is consistent with an ACE function as an amyloid degradation enzyme, which may be important in exceptional longevity in humans. Additionally, the DD genotype causes a high circulating ACE. In contrast, the DD genotype is also associated with an increased risk of various other diseases. They include hypertension (Li et al., 2011), ischemic stroke (Zhang et al., 2012), coronary artery disease (Zintzaras et al., 2008), left ventricular hypertrophy (Li et al., 2012) and pneumonia (Nie et al., 2014). Some of these diseases, including hypertension and cardiovascular conditions (stroke and coronary artery disease), are associated with the risks of COVID-19 mortality (Antos et al., 2021). The DD genotype is associated with higher COVID-19 mortality (Yamamoto et al., 2020). It may imply disease interactions mediated by the D allele. The underlying mechanisms of human longevity remain unclear, especially when considering the D-allele's role as a risk factor for many agerelated comorbidities. Further studies on nonagenarians and centenarians of different backgrounds may provide better insight into the role of ACE as a longevity gene.

Author Contributions: L.L. was involved in data collection, organization of AI components, data analysis and writing of the manuscript. S.M. directed and guided all the research process.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data supporting the reported results have been made available within the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- 1. Antos A, Kwong ML, Balmorez T, Villanueva A, Murakami S. (2021) Unusually High Risks of COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis Method to Improve the Risk Assessment of Mortality Using the Comorbid Mortality Data. Infect Dis Rep. 13(3):700-711. doi: 10.3390/idr13030065. PMID: 34449622; PMCID: PMC8395741.
- 2. Arkhipova, N., Popova, E. and Grigorieva, L. (2014) The angiotension converting enzyme (ACE) gene I/D polymorphism in different ethnic groups of geriatric age living in the Far North. Health, 6, 426-431. doi: 10.4236/health.2014.65060.
 - 3. Batrinos ML. (2008) The length of life and eugeria in classical Greece. Hormones (Athens). 7(1):82-3. doi: 10.14310/horm.2002.1111041. PMID: 18359748.
- 4. Beohar N, Damaraju S, Prather A, Yu QT, Raizner A, Kleiman NS, Roberts R, Marian AJ. (1995) Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Investig Med. 43(3):275-80. PMID: 7614074.
- 5. Bladbjerg EM, Andersen-Ranberg K, de Maat MP, Kristensen SR, Jeune B, Gram J, Jespersen J. (1999) Longevity is independent of common variations in genes associated with cardiovascular risk. Thromb Haemost. 82(3):1100-5. PMID: 10494771.
- 6. Blanché H, Cabanne L, Sahbatou M, Thomas G. (2001) A study of French centenarians: are ACE and APOE associated with longevity? C R Acad Sci III. 324(2):129-35. doi: 10.1016/s0764-4469(00)01274-9. PMID: 11280044.
- 7. Cheng, SH., Augustin, C., Bethel, A., Gill, D., Anzaroot, S., Brun, J., DeWilde, B., Minnich, R., Garside, R., Masuda, Y., Miller, DC., Wilkie, D., Wongbusarakum, S. and McKinnon, MC. (2018) Using machine learning to advance synthesis and use of conservation and environmental evidence. Conservation Biology, 32: 762-764. doi:10.1111/cobi.1311
- 8. Choi YH, Kim JH, Kim DK, Kim JW, Kim DK, Lee MS, Kim CH, Park SC. (2003) Distributions of ACE and APOE polymorphisms and their relations with dementia status in Korean centenarians. J Gerontol A Biol Sci Med Sci. 58(3):227-31. doi: 10.1093/gerona/58.3.m227. PMID: 12634288.
- 9. Costa D, Scognamiglio M, Fiorito C, Benincasa G, Napoli C. Genetic background, epigenetic factors and dietary interventions which influence human longevity. Biogerontology. 2019 Oct;20(5):605-626. doi: 10.1007/s10522-019-09824-3. Epub 2019 Jul 15. PMID: 31309340.
- 10. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. (1993) Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 290 (Pt1)(Pt1):33-40. doi: 10.1042/bj2900033. PMID: 8382480; PMCID: PMC1132379.
- 11. Faure-Delanef L, Baudin B, Bénéteau-Burnat B, Beaudoin JC, Giboudeau J, Cohen D. (1998) Plasma concentration, kinetic constants, and gene polymorphism of angiotensin l-converting enzyme in centenarians. Clin Chem. 44(10):2083-7. PMID: 9761238.
- 12. Fiuza-Luces C, Ruiz JR, Rodríguez-Romo G, Santiago C, Gómez-Gallego F, Cano-Nieto A,
 Garatachea N, Rodríguez-Moreno I, Morán M, Lucia A. (2011) Is the ACE I/D
 polymorphism associated with extreme longevity? A study on a Spanish cohort. J Renin
 Angiotensin Aldosterone Syst. 12(3):202-7. doi: 10.1177/1470320310391505. Epub 2011
 Feb 17. PMID: 21330423.

471 13. Garatachea N, Marín PJ, Lucia A. (2013) The ACE DD genotype and D-allele are
472 associated with exceptional longevity: a meta-analysis. Ageing Res Rev. 12(4):1079-87.
473 doi: 10.1016/j.arr.2013.04.001. Epub 2013 Apr 23. PMID: 23623925.

- 14. Gareri P, Lacava R, Rossi MG, Iorio C, Galasso MA, Pansini L, Curti A, Mercurio M, Olivo D, Mattace R. (1996) Hypertension in a group of centenarians. Arch Gerontol Geriatr. 22 Suppl 1:373-6. doi: 10.1016/0167-4943(96)86964-0. PMID: 18653059.
- 15. Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slagboom PE. (1999) Angiotensin I-converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort. J Am Coll Cardiol. 34(4):1176-83. doi: 10.1016/s0735-1097(99)00337-x. PMID: 10520809.
- 16. Hu J, Igarashi A, Kamata M, Nakagawa H. (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 276(51):47863-8. doi: 10.1074/jbc.M104068200. Epub 2001 Oct 16. PMID: 11604391.
- 17. Jopp DS, Boerner K, Rott C. (2016) Health and Disease at Age 100. Dtsch Arztebl Int. 113(12):203-10. doi: 10.3238/arztebl.2016.0203. Erratum in: Dtsch Arztebl Int. 2016 113(22-23):395. PMID: 27118718; PMCID: PMC5400033.
- 18. Kolovou G, Kolovou V, Vasiliadis I, Giannakopoulou V, Mihas C, Bilianou H, Kollia A, Papadopoulou E, Marvaki A, Goumas G, Kalogeropoulos P, Limperi S, Katsiki N, Mavrogeni S. (2013) The frequency of 4 common gene polymorphisms in nonagenarians, centenarians, and average life span individuals. Angiology. 65(3):210-5. doi: 10.1177/0003319712475075. PMID: 23389097.
- 19. Kölsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, Heun R. (2005) ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Lett. 377(1):37-9. doi: 10.1016/j.neulet.2004.11.062. Epub 2004 Dec 10. PMID: 15722183.
- 20. Le D, Brown L, Malik K, Murakami S. (2021) Two Opposing Functions of Angiotensin-Converting Enzyme (ACE) That Links Hypertension, Dementia, and Aging. Int J Mol Sci. 22(24):13178. doi: 10.3390/ijms222413178. PMID: 34947975; PMCID: PMC8707689.
- 21. Le D, Crouch N, Villanueva A, Ta P, Dmitriyev R, Tsunzi M and Murakami S. (2020) Evidence-Based Genetics and Identification of Key Human Alzheimer's Disease Alleles with Co-morbidities. J Neurol Exp Neurosci 6(1): 20-24.
- 22. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG. (2005) Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol. 162(4):305-17. doi: 10.1093/aje/kwi202. Epub 2005 Jul 20. PMID: 16033878.
- 23. Li X, Li Y, Jia N, Guo S, Chu S, Niu W. (2012) Angiotensin-converting enzyme gene deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-analysis. Mol Biol Rep. 39(12):10063-75. doi: 10.1007/s11033-012-1875-6. Epub 2012 Jul 7. PMID: 22773337.
- 24. Li Y. (2012) Angiotensin-converting enzyme gene insertion/deletion polymorphism and essential hypertension in the Chinese population: a meta-analysis including 21,058 participants. Intern Med J. 2012 Apr;42(4):439-44. doi: 10.1111/j.1445-5994.2011.02584.x. PMID: 21883781.

25. Lo Sasso, B., Bellia, C., Tomaiuolo, R., Zarrilli, F., Scorza, M., Caruso, A., et al. (2013).
 Polimorfismo I/D del gene per l'enzima di conversione dell'angiotensina (ACE): gene
 della longevità o fattore di rischio nella patologia ipertensiva?. Biochimica Clinica,
 37(37), 461-464.

- 26. Machino K, Link CD, Wang S, Murakami H, Murakami S. A semi-automated motion-tracking analysis of locomotion speed in the C. elegans transgenics overexpressing beta-amyloid in neurons. Front Genet. 2014 Jul 4;5:202. doi: 10.3389/fgene.2014.00202. PMID: 25071831; PMCID: PMC4082091.
- 27. McGuinness LA, Higgins JPT. (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 12(1):55-61. doi: 10.1002/jrsm.1411. PMID: 32336025.
 - 28. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7):e1000097. doi: 10.1371/journal.pmed.1000097. PMID: 19621072; PMCID: PMC2707599.
- 29. Montagu JD. (1994) Length of life in the ancient world: a controlled study. J R Soc Med. 87(1):25-6. PMID: 8308825; PMCID: PMC1294277.
- 30. Murakami, S. (2013) Age-dependent modulation of learning and memory in C. elegans. In Menzel R and Benjamin P.R. (Eds.) Invertebrate Learning and Memory; Handbook of Behavioral Neuroscience. Elsevier/Academic Press. Ch.12, Pages 140-150.
- 31. Murakami, S., Cabana, K., Anderson, D. (2011) Current advances in the study of oxidative stress and age-related memory impairment in *C. elegans*. In Farooqui, T. Farooqui, A. (Ed.) Molecular aspects of oxidative stress on cell signaling in vertebrates and invertebrates, John Wiley & Sons, Hoboken, NJ. Ch 25, Pages 347-360.
- 32. Murakami S, Lacayo P. (2022) Biological and disease hallmarks of Alzheimer's disease defined by Alzheimer's disease genes. Front Aging Neurosci. 14:996030. doi: 10.3389/fnagi.2022.996030. PMID: 36437990; PMCID: PMC9682170.
- 33. Nacmias B, Bagnoli S, Tedde A, Cellini E, Bessi V, Guarnieri B, Ortensi L, Piacentini S, Bracco L, Sorbi S. (2007) Angiotensin converting enzyme insertion/deletion polymorphism in sporadic and familial Alzheimer's disease and longevity. Arch Gerontol Geriatr. 45(2):201-6. doi: 10.1016/j.archger.2006.10.011. Epub 2006 Dec 19. PMID: 17182125.
- 34. Nie W, Zang Y, Chen J, Liu T, Xiao L, Xiu Q. (2014) Angiotensin-converting enzyme I/D polymorphism is associated with pneumonia risk: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 15(4):585-92. doi: 10.1177/1470320313507622. Epub 2014 Feb 4. PMID: 24496515.
- 35. Oscanoa TJ, Cieza EC, Lizaraso-Soto FA, Guevara ML, Fujita RM, Romero-Ortuño R. (2020) Angiotensin-Converting Enzyme (ACE) genetic variation and longevity in Peruvian older people: a cross-sectional study. Ann Hum Biol. 47(3):309-312. doi: 10.1080/03014460.2020.1748227. PMID: 32281429.
- 36. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L,
 Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu
 MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J,
 Tricco AC, Welch VA, Whiting P, Moher D. (2021) The PRISMA 2020 statement: an

updated guideline for reporting systematic reviews. BMJ. 372:n71. doi: 10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.

- 37. Panza, F., Solfrizzi, V., D'Introno, A., Capurso, C., Basile, A.M., Colacicco, A.M., Sabba, M., Noya, R., Capurso, A. (2002) Apolipoprotein and angiotensin converting enzyme genes: regional differences and extreme longevity in Europe. Archives of Gerontology and Geriatrics Supplement 8, 247–251
- 38. Panza F, Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Kehoe PG, Capurso A. (2003) Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: different allele frequencies between the North and South of Europe. Exp Gerontol. 38(9):1015-20. doi: 10.1016/s0531-5565(03)00154-2. PMID: 12954489.
- 39. Pereira da Silva A, Matos A, Aguiar L, Ramos-Marques N, Ribeiro R, Gil Â, Gorjão-Clara J, Bicho M. (2019) Hypertension and longevity: role of genetic polymorphisms in reninangiotensin-aldosterone system and endothelial nitric oxide synthase. Mol Cell Biochem. 455(1-2):61-71. doi: 10.1007/s11010-018-3470-1. PMID: 30460536.
- 40. Revelas M, Thalamuthu A, Oldmeadow C, Evans TJ, Armstrong NJ, Kwok JB, Brodaty H, Schofield PR, Scott RJ, Sachdev PS, Attia JR, Mather KA. (2018) Review and meta-analysis of genetic polymorphisms associated with exceptional human longevity. Mech Ageing Dev. 175:24-34. doi: 10.1016/j.mad.2018.06.002. PMID: 29890178.
- 41. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86(4):1343-6. doi: 10.1172/JCI114844. PMID: 1976655; PMCID: PMC296868.
- 42. Roser M, Ortiz-Ospina E, Ritchie H (2013) Life Expectancy. OurWorldInData.org. Retrieved on Nov 29, 2022 from: https://ourworldindata.org/life-expectancy
- 43. Schächter F, Faure-Delanef L, Guénot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet. 6(1):29-32. doi: 10.1038/ng0194-29. PMID: 8136829.
- 44. Seripa D, Franceschi M, Matera MG, Panza F, Kehoe PG, Gravina C, Orsitto G, Solfrizzi V, Di Minno G, Dallapiccola B, Pilotto A. (2006) Sex differences in the association of apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy aging and longevity: a population-based study from Southern Italy. J Gerontol A Biol Sci Med Sci. 61(9):918-23. doi: 10.1093/gerona/61.9.918. PMID: 16960022.
- 45. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 355:i4919. doi: 10.1136/bmj.i4919. PMID: 27733354; PMCID: PMC5062054.
- 46. Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M, Yamamoto M, Ueda R. (1997) Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med. 156(1):255-9. doi: 10.1164/ajrccm.156.1.9612011. PMID: 9230757.

- 47. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992 Jul;51(1):197-205. PMID: 1319114; PMCID: PMC1682892.
- 48. Vahdati Nia B, Kang C, Tran MG, Lee D, Murakami S. (2017) Meta Analysis of Human AlzGene Database: Benefits and Limitations of Using *C. elegans* for the Study of Alzheimer's Disease and Co-morbid Conditions. Front Genet. 2017 8:55. doi: 10.3389/fgene.2017.00055. PMID: 28553317; PMCID: PMC5427079.
- 49. Weinert BT, Timiras PS. Theories of aging. J Appl Physiol. (2003) 95(4):1706-16. doi: 10.1152/japplphysiol.00288.2003. PMID: 12970376.
- 50. Wufuer M, Fang MW, Cheng ZH, Qiu CC. (2004) [Polymorphism of angiotensin converting enzyme gene and natural longevity in the Xinjiang Uygur people: an association study]. Zhonghua Yi Xue Za Zhi. 84(19):1603-6. Chinese. PMID: 15569453.
- 51. Yang JK, Gong YY, Xie L, Lian SG, Yang J, Xu LY, Gao SJ, Zhang YP. (2009) Lack of genetic association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and longevity in a Han Chinese population. J Renin Angiotensin Aldosterone Syst. 10(2):115-8. doi: 10.1177/1470320309104873. PMID: 19502260.
- 52. Zhang WF, Ling JH, Wang AJ. (2010) [Relationship between shen-deficiency syndrome and polymorphism of angiotensin converting enzyme gene in longevous elders in Bama area of Guangxi municipality]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 30(3):259-63. Chinese. PMID: 20535922.
- 53. Zintzaras E, Raman G, Kitsios G, Lau J. (2008) Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis. Arch Intern Med. 168(10):1077-89. doi: 10.1001/archinte.168.10.1077. PMID: 18504336.